Business
Microbix & Aurevia Introduce Novel EQA Scheme
MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems ...
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"Microbix & Aurevia Introduce Novel EQA SchemePilot Program for Qualifying Clinical Labs to Diagnose Bacterial Vaginosis\n\n\n\n MISSISSAUGA, Ontario and HELSINKI, Finland, May 13, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (\n \n TSX: MBX, OTCQX: MBXBF, Microbix®\n \n ), a life sciences innovator, manufacturer, and exporter, and Aurevia Oy via its Labquality EQAS affiliate (\n \n Aurevia\n \n ), announce a pilot external quality assessment (“\n \n EQA\n \n ”) program to help clinical laboratories establish their proficiency at using molecular diagnostic methods (e.g., PCR tests) to diagnose bacterial vaginosis (“\n \n BV\n \n ”).\n \n\n BV is a common vaginal condition that will affect a large percentage of women during adulthood. BV is caused by an imbalance in the bacterial flora of the vagina, with non-beneficial species becoming dominant. BV has historically been diagnosed by changes in vaginal acidity, odor, or by microbiology – methods which are sometimes not definitive. In contrast, molecular diagnostic (“\n \n MDx\n \n ”) tests can distinguish each of the organisms that should be present in vaginal flora and detect whether their proportions are normal. Accordingly, MDx tests for BV can provide definitive diagnoses and help determine a treatment plan.\n \n\n The EQA program being introduced by Aurevia is number 5305, titled “\n \n Bacterial vaginosis and vaginitis multiplex nucleic acid detection\n \n .” The current pilot study is intended for clinical labs diagnosing BV, as well as other vaginal infections, such as vulvovaginal candidiasis and trichomoniasis. The program will be run with simulated samples made by Microbix (“\n \n QAPs™\n \n ”). After completion of the pilot study and analysis of its results, it is anticipated that an ongoing program for BV will be added to the Aurevia Labquality EQAS portfolio of EQA schemes to which clinical laboratories testing for BV can subscribe.\n \n\n Microbix QAPs are designed to fully emulate clinical specimens from patients while being safe and stable. For this BV pilot program, Microbix has created three QAPs samples formatted onto Copan® FLOQSwabs® – to correctly emulate the workflow of MDx tests for BV from collection of patient specimens through to the reporting ...